share_log

BriaCell Therapeutics Analyst Ratings

BriaCell Therapeutics Analyst Ratings

BriaCell Therapeutics分析師評級
Benzinga ·  2023/10/04 00:01
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/03/2023 242.47% HC Wainwright & Co. $25 → $20 Maintains Buy
06/28/2023 328.08% HC Wainwright & Co. → $25 Reiterates Buy → Buy
02/24/2023 328.08% HC Wainwright & Co. → $25 Reiterates → Buy
02/14/2022 328.08% HC Wainwright & Co. → $25 Initiates Coverage On → Buy
日期 上行/下行空間 分析師公司 價格目標變更 評級變化 之前/現今評級
10/03/2023 242.47% HC Wainwright & Co. $25 → $20 維持不變 買入
06/28/2023 328.08% HC Wainwright & Co. → 25美元 重申 買入 → 買入
02/24/2023 328.08% HC Wainwright & Co. → 25美元 重申 買入
02/14/2022 328.08% HC Wainwright & Co. → 25美元 開始覆蓋 買入

What is the target price for BriaCell Therapeutics (BCTX)?

BriaCell Therapeutics (BCTX)的目標價是多少?

The latest price target for BriaCell Therapeutics (NASDAQ: BCTX) was reported by HC Wainwright & Co. on October 3, 2023. The analyst firm set a price target for $20.00 expecting BCTX to rise to within 12 months (a possible 242.47% upside). 3 analyst firms have reported ratings in the last year.

BriaCell Therapeutics (NASDAQ:BCTX) 的最新目標價由HC Wainwright & Co.於2023年10月3日報告。該分析師公司設定了一個20.00美元的目標價,預計BCTX在12個月內上漲(可能有242.47%的上漲空間)。過去一年裏有3家分析師公司報告了評級。

What is the most recent analyst rating for BriaCell Therapeutics (BCTX)?

BriaCell Therapeutics (BCTX)的最新分析師評級是什麼?

The latest analyst rating for BriaCell Therapeutics (NASDAQ: BCTX) was provided by HC Wainwright & Co., and BriaCell Therapeutics maintained their buy rating.

BriaCell Therapeutics (NASDAQ:BCTX)的最新分析師評級由HC Wainwright & Co.提供,並且BriaCell Therapeutics保持了買入評級。

When is the next analyst rating going to be posted or updated for BriaCell Therapeutics (BCTX)?

BriaCell Therapeutics (BCTX)下一位分析師評級將於何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BriaCell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BriaCell Therapeutics was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.

分析師進行深入研究後才會做出股票評級,這包括查閱公開的基本報表、與BriaCell Therapeutics的高管和客戶交流,以及聽取業績會議的錄音。大多數分析師每季度進行一次此類研究,因此您每年應該會得到4個公司的評級。BriaCell Therapeutics的最新評級是在2023年10月3日提交的,因此您可以期望下一個評級將在2024年10月3日左右公佈。

Is the Analyst Rating BriaCell Therapeutics (BCTX) correct?

BriaCell Therapeutics (BCTX)的分析師評級是否正確?

While ratings are subjective and will change, the latest BriaCell Therapeutics (BCTX) rating was a maintained with a price target of $25.00 to $20.00. The current price BriaCell Therapeutics (BCTX) is trading at is $5.84, which is out of the analyst's predicted range.

儘管評級是主觀的且會發生變化,但BriaCell Therapeutics (BCTX)的最新評級是維持現狀,目標價爲$25.00至$20.00。BriaCell Therapeutics (BCTX)目前的交易價格爲$5.84,超出了分析師預測的區間。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論